The effects of metformin on glycemic control and serum lipids in insulin-treated NIDDM patients with suboptimal metabolic control

Diabetes Care

Volumn 21, Issue 5, 1998, Pages 701-705

  Robinson, Adam C ^a   Burke, John ^b   Robinson, Stephen ^a   Johnston, Desmond G ^a   Elkeles, Robert S ^a  

^a IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

^b BARNET HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN A1C; INSULIN; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; GLUCOSE HOMEOSTASIS; HUMAN; HYPOGLYCEMIA; INSULIN TREATMENT; LIPOPROTEIN BLOOD LEVEL; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL; TRIACYLGLYCEROL BLOOD LEVEL;

AGED; BLOOD GLUCOSE; BLOOD PRESSURE; BODY WEIGHT; CHOLESTEROL; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CROSS-OVER STUDIES; DATA INTERPRETATION, STATISTICAL; DIABETES MELLITUS, TYPE 2; DIASTOLE; DOUBLE-BLIND METHOD; FASTING; FEMALE; GLUCOSE TOLERANCE TEST; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; LIPIDS; MALE; METFORMIN; MIDDLE AGED; SYSTOLE; TREATMENT OUTCOME; TRIGLYCERIDES;

EID: 0031767174     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.21.5.701     Document Type: Article

References (27)

1. DeFronzo RA, Goodman AM; Efficacy of metformin in patients with noninsulindependent diabetes mellitus: the Multicenter Metformin Study Group. N Engl J Med 333:541-549, 1995
2. Rains SG, Wilson GA, Richmond W, Elkeles RS: The effect of glibenclamide and metformin on serum lipoproteins in type 2 diabetes. Diabet Med 5:653-658, 1988
3. Wu MS, Johnston P, Sheu WH, Hollenbeck CB, Jeng CY, Goldfme ID, Chen YD, Reaven GM: Effect of metformin on carbohydrate and lipoprotein metabolism in NIDDM patients. Diabetes Care 13:1-8, 1990
4. Rains SG, Wilson GA, Richmond W, Elkeles RS: The reduction of low density lipoprotein cholesterol by metformin is maintained with long-term therapy. JR Soc Med 82:93-94, 1989
5. Nagi DK, Yudkin JS: Effects of metformin on insulin resistance, risk factors for cardiovascular disease, and plasminogen activator inhibitor in NIDDM subjects: a study of two ethnic groups. Diabetes Care 16:621-629, 1993
6. Campbell IW, Hewlett HC: Worldwide experience of metformin as an effective glucose-lowering agent: a meta-analysis. Diabetes Metab Rev 11:S57-S62, 1995
7. Bailey CJ, Turner RC: Metformin. N Engl J Med 334:574-579, 1996
8. Friedewald WT, Levy RI, Fredrickson DS: Estimation of the concentration of lowdensity lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18:499-502, 1972
9. Hills M, Armitage P: The two-period crossover clinical trial. Er J Clin Pharmacol 8:7-20, 1979
10. Nelson RG, Wolfe JA, Horton MB, Pettitt DJ, Bennett PH, Knowler WC: Proliferative retinopathy in NIDDM: incidence and risk factors in Pima Indians. Diabetes 38:435-440, 1989
11. Vaccaro O, Rivellese A, Annuzzi G, Riccardi G, Fumari M, Rubba P, Mancini M: Risk factors for peripheral atherosclerosis in non insulin dependent diabetes. Artery 10:341-352, 1982
12. Damsgaard EM, Froland A, Green A: Use of hospital services by elderly diabetics: the Frederica Study of diabetic and fasting hyperglycaemic patients aged 60-74 years. Diabet Med 4:317-321, 1987
13. Derfler K, Waldhausl W, Zyman HJ, Howorka K, Holler C, Freyler H: Diabetes care in rural area: clinical and metabolic evaluation. Diabetes Care 9:509-517, 1986
14. Abraira C, Colwell JA, Nuttall FQ, Sawin CT, Nagel NJ, Comstock JR Emanuele NY Levin SR, Henderson W, Lee HS: Veterans Affairs Cooperative Study on Glycemie Control and Complications in Type II Diabetes (VA CSDM): results of the feasibility trial: Veterans Affairs Cooperative Study in Type II Dia- betes. Diabetes Care 18:1113-1123, 1995
15. Johnson JL, Wolf SL, Kabadi UM: Efficacy of insulin and sulfonylurea combination therapy in type II diabetes: a meta-analysis of the randomized placebo-controlled trials. Arch Intern Med 156:259-264, 1996
16. Ruas MM, Carvalheiro M, Geraldes E, Carrilho F, Bastos M, Fagulha A, Paiva I, Rodrigues F, Gomes L: Beneficial effects of added glicazide in patients with type 11 diabetes mellitus treated with insulin. Acta Med Port 4:76-78, 1991
17. Bailey CJ: Biguanides and NIDDM. Diabetes Care 15:755-772, 1992
18. Lucis OJ: The status of metformin in Canada. Can Med Assoc J 128:24-26, 1983
19. Giugliano D, Quatraro A, Consoli G, Minei A, Ceriello A, De Rosa N, D'Onofrio F: Metformin for obese, insulin-treated diabetic patients: improvement in glycaemic control and reduction of metabolic risk factors. EurjainPharmacoI44:107-112, 1993
20. Campbell IW, Menzies DG, Chalmers J, McBain AM, Brown IR: One year comparative trial of metformin and glipizide in type 2 diabetes mellitus. Diabetes Metab 20:394-400, 1994
21. Stumvoll M, Nurjhan N, Perriello G, Dailey G, Gerich JE: Metabolic effects of metformin in non-insulin-dependent diabetes mellitus. N Engl J Med 333:550-554, 1995
22. United Kingdom Prospective Diabetes Study (UKPDS): Relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years. BMJ 310:83-88, 1995
23. Lalor BC, Bhatnagar D, Winocour PH, Ishola M, Arrol S, Grading M, Durrington PN: Placebo-controlled trial of the effects of guar gum and metformin on fasting blood glucose and serum lipids in obese, type 2 diabetic patients. Diabet Med 7:242-245, 1990
24. Hermann LS, Karlsson JE, Sjostrand A: Prospective comparative study in NIDDM patients of metformin and glibenclamide with special reference to lipid profiles, Eur J Clin Pharmacol 41:263-265, 1991
25. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, McKillop JH, Packard CJ: Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia: West of Scotland Coronary Prevention Study Group. N Engl J Med 333:1301-1307, 1995
26. Gutniak M, Karlander SG, Efendic S: Glyburide decreases insulin requirement, increases beta-cell response to mixed meal, and does not affect insulin sensitivity: effects of short- and long-term combined treatment in secondary failure to sulfonylurea. Diabetes Care 10:545-554, 1987
27. Chow CC, Tsang LW, Sorensen JP, Cockram CS: Comparison of insulin with or without continuation of oral hypoglycemie agents in the treatment of secondary failure in NIDDM patients. Diabetes Care 18:307-314, 1995